The 7th CKD Drug Development Summit Returns to Boston to Shape the Future of Renal Therapeutics

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support with accelerated approval pathways. With new drug classes reshaping treatment paradigms and soaring interest in precision medicine, the industry resides in a transformative era of renal innovation.

Returning this March 2025, in Boston, MA, the 7th CKD Drug Development Summit is the definitive forum uniting 200+ biopharma leaders, nephrology experts, and regulatory decision-makers to tackle the biggest challenges in CKD therapeutic development from discovery to approval.

With an agenda built in collaboration with industry pioneers, this year's summit will cover:

Discover the latest breakthroughs in renal research from industry giants like AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Bayer, Roche, and Pfizer. Assess how recent therapeutic advancements are reshaping the CKD treatment landscape and driving the search for novel targets.

Gain insights into designing clinical trials in a crowded therapeutic field while ensuring patient safety and trial integrity. Expand your understanding of glomerular diseases beyond IgA Nephropathy with focused discussions on FSGS, Lupus Nephritis, C3G, and Membranous Nephropathy. Plus, you will gain strategic regulatory insights into endpoints, trial design, and approvals, equipping you to stay ahead in renal drug development.

As the only dedicated summit bringing together the full CKD drug development ecosystem, this meeting provides an unparalleled opportunity to connect with top nephrology innovators, benchmark your development strategies, and shape the future of rare and common chronic kidney disease research and development.

For more information about the 7th CKD Summit 2025, visit: www.ckd3-summit.com.